FindTrial
Sign In

Trace element loss in the regional citrate anticoagulation in continous renal replacement therapy

Trace element loss in the regional citrate anticoagulation in continous renal replacement therapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16010163
Enrollment
Unknown
Registered
2016-12-15
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury,chronic kidney disease

Interventions

1:Heparin anticoagulation
2:Regional citrate anticoagulation

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. patients with severe acute kidney injury or chronic kidney disease; 2. requiring continuous renal replacement therapy; 3. All the patients signed a consent form.

Exclusion criteria

Exclusion criteria: 1. Duration of continuous renal replacement therapy less than 8 hours; 2. The pregnant patient; 3. The patients with age less than 18 years; 4. The patients have contraindications to heparins anticoagulation; 5. The patients have contraindications to regional citrate anticoagulation.

Design outcomes

Primary

MeasureTime frame
loss of trace elements;—

Countries

China

Contacts

Public ContactWu Buyun

the First Affiliated Hospital of Nanjing Medical University?

wubuyun@njmu.edu.cn+86 15950594895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026